Nirogacestat vs Varegacestat
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Desmoid Tumors
Shared mechanism: Gamma-secretase (presenilin complex) · full Desmoid Tumors pipeline
Nirogacestat
Marketed by Merck KGaA and partners
NCT03785964 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 142 participants with a hard clinical tumor endpoint, progression-free survival. The primary comparison was statistically significant in favor of nirogacestat: median progression-free survival was not reached with nirogacestat versus 15.1 months with placebo, with HR 0.29 (95% CI 0.15–0.55; p<0.001).
Next expected readout: January 2027 · NCT05879146 (registry estimate)
No aligned efficacy figure on record for this race.
Varegacestat
Developed by Immunome, Inc.
NCT04871282 · Phase 2/3 · active, not recruiting
This was a randomized, quadruple-masked Phase 2/3 trial with 198 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-12-15. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Part A: Safety and Tolerability - Adverse Events (Approximately 1.5 years); Part B: Progression free survival (PFS) (Approximately 2 years): Primary endpoint, progression-free survival vs placebo: HR 0.16 (95% CI 0.071-0.375; p<0.0001); confirmed ORR 56% vs 9% (RINGSIDE, 2025-12-15). (met)
Result source: NCT04871282
Results for Desmoid Tumors
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nirogacestat: registry results are on file for Desmoid Tumors, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nirogacestat's landscape · Varegacestat's landscape